- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03043222
Innovative Minimally Invasive Options in Treatment of Urinary Problems Related to Prostate Enlargement (BPH) in Men
Effect of Prostatic Urethral Lift (PUL) Versus Prostate Arterial Embolization (PAE),Novel Minimally Invasive Treatment Options on Health-related Quality of Life (HRQoL) in Men With Lower Urinary Tract Symptoms Secondary to BPH.
For ageing men, Health related quality of life ( HRQoL) is challenged by two common issues: the onset of bothersome urinary symptoms attributable to prostate enlargement and diminishing ability to maintain normal sexual activity and function; both issues are important to men, yet often the treatment of the former has adverse effects on the latter. Current medical and surgical treatments offer symptomatic improvement of urinary symptoms. However long recovery times, degradation of sexual function and incontinence may negatively affect a patient's QoL.
Prostatic urethral lift (PUL) and prostate artery embolization (PAE) represent two evolving techniques with contrasting mechanisms of action (mechanical decompression vs angiographic embolization). Both are minimally invasive, yield relief of urinary symptoms and have similar safety profiles. More importantly neither causes degradation of sexual function or urinary continence. Although multiple studies are being reported on PUL and PAE alike, currently there are no prospective clinical trials comparing these two technologies. We aim to prospectively evaluate and compare HRQol outcomes of PUL and PAE. Results of this study could have a great impact on patient outcomes in men opting for minimally invasive, sexual function sparing treatment options for symptom relief from prostate enlargement.
Study Overview
Status
Conditions
Detailed Description
As the population ages, there is a growing need to find ways for people to live longer with satisfactory quality of life (QoL), even in the midst of increasing health problems. For the ageing man, Health related quality of life ( HRQoL) is challenged by two common issues: the onset of bothersome LUTS attributable to benign prostatic hypertrophy (BPH) and diminishing ability to maintain normal sexual activity and function; both issues are important to men, yet often the treatment of the former has adverse effects on the latter.
Current medical and surgical treatments like TURP for BPH offer symptomatic improvement of LUTS but may adversely affect a patient's QOL and satisfaction. Peri-operative complications and long recovery times, degradation of sexual function and iatrogenic incontinence may negatively affect a patient's QoL overall, resulting in patient viewing this as a treatment failure. Therefore when evaluating treatment options for BPH, treatment options with important QOL measures of satisfaction have to be considered.
Prostatic urethral lift (PUL) and prostate artery embolization (PAE) represent two evolving techniques with contrasting mechanisms of action (mechanical decompression vs angiographic embolization). Multiple prospective and retrospective studies have shown that both PUL and PAE yield relief of lower urinary tract symptoms over a period of several weeks. They display similar safety profiles with self-limiting pelvic discomfort characterizing the commonest minor adverse event. Both procedures are minimally invasive and have the potential to be carried out under local anesthesia and in the outpatient setting with suitability for patients with cardiovascular comorbidities. Another important finding is that neither has been found to cause degradation of sexual function.
Although there are an increasing number of data series being reported on PUL and PAE alike, currently there are no prospective clinical trials comparing these two technologies. We aim to prospectively evaluate and compare HRQol outcomes of PUL and PAE. All the endpoints will be evaluated using validated questionnaires and laboratory values. Results of this study will be transferable to clinical practice and could have a great impact on patient outcomes in men opting for minimally invasive, sexual function sparing treatment options for symptom relief from LUTS due to BPH in all practice settings.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Saint Louis University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Male aged ≥40 yr Willing, able and mentally competent to provide written informed consent and willing to comply with all study procedures and be available for the duration of the study Diagnosis of urinary symptoms (LUTS) from prostatic enlargement (BPH) refractory to medical therapy for at least 6 months.
International Prostate Symptom Score >12
Exclusion Criteria:
PUL
- Active urinary tract infections, prostatitis, or interstitial cystitis.
Biopsy proven prostate, bladder, or urethral cancer.
The following patients must undergo prostate biopsy with a minimum of 12 cores and have a negative histopathology report to be enrolled in the study:
- Patients with digital rectal examination (DRE) findings suspicious for prostate cancer
- Patients with baseline PSA levels > 10 ng/mL
- Patients with baseline PSA levels >2.5 ng/mL and < 10ng/mL AND free PSA < 25% of total PSA Patients with cystoscopy findings suspicious for bladder cancer must undergo biopsy and have a negative histopathology report to be enrolled in the study
- Significant median lobe enlargement.
- Large prostates, volume >80 g.
- Bladder atonia, neurogenic bladder disorder or other neurological disorder that is impacting bladder function (e.g. multiple sclerosis, Parkinson's disease, spinal cord injuries, etc.)
- Urethral stricture, bladder neck contracture, sphincter abnormalities, bladder diverticulum, urinary obstruction due to causes other than BPH, or other potentially confounding bladder or urethral disease or condition
- Urethral conditions that may prevent insertion of a rigid 20F cystoscope
- Current urinary retention.
- Acontractile detrusor.
- Current gross hematuria
- Known upper tract renal disease
- Cystolithiasis
- ASA > 3 or severe medical debilitating condition
- History of pelvic irradiation or radical pelvic surgery
Known allergy to nickel.
PAE
- Active urinary tract infections, prostatitis, or interstitial cystitis.
Biopsy proven prostate, bladder, or urethral cancer.
The following patients must undergo prostate biopsy with a minimum of 12 cores and have a negative histopathology report to be enrolled in the study:
- Patients with digital rectal examination (DRE) findings suspicious for prostate cancer
- Patients with baseline PSA levels > 10 ng/mL
- Patients with baseline PSA levels >2.5 ng/mL and < 10ng/mL AND free PSA < 25% of total PSA Patients with cystoscopy findings suspicious for bladder cancer must undergo biopsy and have a negative histopathology report to be enrolled in the study
- Unable to have CT angio of the prostate imaging
- Bladder atonia, neurogenic bladder disorder or other neurological disorder that is impacting bladder function (e.g. multiple sclerosis, Parkinson's disease, spinal cord injuries, etc.)
- Urethral stricture, bladder neck contracture, sphincter abnormalities, bladder diverticulum, urinary obstruction due to causes other than BPH, or other potentially confounding bladder or urethral disease or condition
- Acontractile detrusor.
- Known upper tract renal disease
- Cystolithiasis
- Any known condition that limits catheter-based intervention or is a contraindication to embolization, such as intolerance to a vessel occlusion procedure or severe atherosclerosis. Known major iliac arterial occlusive disease
- ASA > 3 or severe medical debilitating condition
- Baseline serum creatinine level > 1.8 mg/dl
- Previous rectal surgery other than hemorrhoidectomy, or history of rectal disease
- History of pelvic irradiation or radical pelvic surgery
- Allergy to iodinated contrast agents
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PAE-Prostate Arterial Embolization
|
UroLift as artifical device for prostatic urethral lift.
The PUL treatment is a minimally invasive approach to treating an enlarged prostate, or BPH, that lifts or holds the enlarged prostate tissue using clips so that it is out of the way so it no longer blocks the urethra.
There is no cutting, heating or removal of prostate tissue.
Other Names:
Embospheres Microspheres as embolic agents for prostate artery embolization Arterial access will be obtained.Under live X-ray monitoring and using contrast, a catheter will be advanced into the artery to the prostate gland.Small micro spherical particles (Embopheres Microspheres) will be injected though the catheter to occlude the artery and cut off blood supply to the enlarged prostate.
The prostate is then expected to shrink , thus relieving urinary symptoms related to prostate enlargement.There is no cutting or removal of prostate tissue.Once the procedure is complete, in case of wrist access compression will be achieved with a band; in case of groin access a closure device will be used to plug the site of entry.
Other Names:
|
Active Comparator: PUL- Prostatic urethral lift
|
UroLift as artifical device for prostatic urethral lift.
The PUL treatment is a minimally invasive approach to treating an enlarged prostate, or BPH, that lifts or holds the enlarged prostate tissue using clips so that it is out of the way so it no longer blocks the urethra.
There is no cutting, heating or removal of prostate tissue.
Other Names:
Embospheres Microspheres as embolic agents for prostate artery embolization Arterial access will be obtained.Under live X-ray monitoring and using contrast, a catheter will be advanced into the artery to the prostate gland.Small micro spherical particles (Embopheres Microspheres) will be injected though the catheter to occlude the artery and cut off blood supply to the enlarged prostate.
The prostate is then expected to shrink , thus relieving urinary symptoms related to prostate enlargement.There is no cutting or removal of prostate tissue.Once the procedure is complete, in case of wrist access compression will be achieved with a band; in case of groin access a closure device will be used to plug the site of entry.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in QOL
Time Frame: 3,6,12 months
|
Improvement in QOL score
|
3,6,12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with clinical adverse events
Time Frame: 1 day, 8 days and 1,3,6,12 months
|
Short and medium term complications assessed by Clavien-Dindo Classification of Surgical Complications
|
1 day, 8 days and 1,3,6,12 months
|
Post operative morbidity
Time Frame: 1 day, 8 days and 1 month
|
Morbidity (Intraprocedural and periprocedural data): Pain, hematuria, Procedure time, radiation parameters, duration of post procedure catheterization and hospitalization
|
1 day, 8 days and 1 month
|
Recovery experience
Time Frame: 1 day, 8 days and 1 month
|
Recovery experience based on Quality of life (QoL) Visual Analog Scale( VAS)
|
1 day, 8 days and 1 month
|
Improvement in symptoms of LUTS
Time Frame: 3,6,12 months
|
Reduction in International Prostate Symptom Score (IPSS) compared to baseline
|
3,6,12 months
|
Lack of change in sexual function
Time Frame: 3,6,12 months
|
Reduction of Sexual Health Inventory For Men (SHIM) score compared to baseline
|
3,6,12 months
|
Lack of change in ejaculation during sex
Time Frame: 3,6,12 months
|
Change in Male Sexual Health Questionnaire to assess ejaculatory dysfunction (MSHQ-EjD)
|
3,6,12 months
|
Lack of change in urinary incontinence
Time Frame: 3,6,12 months
|
Change in Incontinence severity index (ISI) score
|
3,6,12 months
|
Change in Urinary flow after procedure
Time Frame: 3,6,12 months
|
Change in Urinary maximal flow rate (Qmax) measured in ml/s on uroflowmetry.
|
3,6,12 months
|
Change in Prostate volume after procedure
Time Frame: 3,6,12 months
|
Change in Prostate volume measured in cm3
|
3,6,12 months
|
Change in residual urine left in bladder after procedure
Time Frame: 3,6,12 months
|
Change in Postvoid residual urine volume measured in ml
|
3,6,12 months
|
Change in Prostatic specific antigen (PSA) after procedure
Time Frame: 3,6,12 months
|
Change in PSA level measured in pg/ml
|
3,6,12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Keith Pereira, MD, Saint Louis University Hospital
- Principal Investigator: Beneranda Sophia Ford-Glanton, MD, Saint Louis University Hospital
Publications and helpful links
General Publications
- McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, Foster HE Jr, Gonzalez CM, Kaplan SA, Penson DF, Ulchaker JC, Wei JT. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011 May;185(5):1793-803. doi: 10.1016/j.juro.2011.01.074. Epub 2011 Mar 21.
- Roehrborn CG, Rukstalis DB, Barkin J, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, Cantwell AL, McVary KT, Te AE, Gholami SS, Moseley WG, Chin PT, Dowling WT, Freedman SJ, Incze PF, Coffield KS, Borges FD, Rashid P. Three year results of the prostatic urethral L.I.F.T. study. Can J Urol. 2015 Jun;22(3):7772-82.
- Sonksen J, Barber NJ, Speakman MJ, Berges R, Wetterauer U, Greene D, Sievert KD, Chapple CR, Montorsi F, Patterson JM, Fahrenkrug L, Schoenthaler M, Gratzke C. Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. Eur Urol. 2015 Oct;68(4):643-52. doi: 10.1016/j.eururo.2015.04.024. Epub 2015 Apr 30.
- Pisco JM, Rio Tinto H, Campos Pinheiro L, Bilhim T, Duarte M, Fernandes L, Pereira J, Oliveira AG. Embolisation of prostatic arteries as treatment of moderate to severe lower urinary symptoms (LUTS) secondary to benign hyperplasia: results of short- and mid-term follow-up. Eur Radiol. 2013 Sep;23(9):2561-72. doi: 10.1007/s00330-012-2714-9. Epub 2013 Jan 31. Erratum In: Eur Radiol. 2013 Sep;23(9):2573-4.
- Bagla S, Martin CP, van Breda A, Sheridan MJ, Sterling KM, Papadouris D, Rholl KS, Smirniotopoulos JB, van Breda A. Early results from a United States trial of prostatic artery embolization in the treatment of benign prostatic hyperplasia. J Vasc Interv Radiol. 2014 Jan;25(1):47-52. doi: 10.1016/j.jvir.2013.09.010. Epub 2013 Oct 28.
- Uflacker AB, Haskal ZJ. Internal Iliac Artery Embolization for Benign Prostatic Hyperplasia? First Read the Fine Print. J Vasc Interv Radiol. 2015 Sep;26(9):1311-2. doi: 10.1016/j.jvir.2015.06.024. No abstract available.
- Pisco JM, Bilhim T, Pinheiro LC, Fernandes L, Pereira J, Costa NV, Duarte M, Oliveira AG. Medium- and Long-Term Outcome of Prostate Artery Embolization for Patients with Benign Prostatic Hyperplasia: Results in 630 Patients. J Vasc Interv Radiol. 2016 Aug;27(8):1115-22. doi: 10.1016/j.jvir.2016.04.001. Epub 2016 Jun 16.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 27936
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lower Urinary Tract Symptoms
-
The Royal College of Surgeons of EnglandUniversity College, LondonCompletedUncomplicated Lower Urinary Tract Symptoms
-
National Taiwan University HospitalUnknownDisorder of the Lower Urinary TractTaiwan
-
ProVerum MedicalNot yet recruitingBPH With Symptomatic Lower Urinary Tract Symptoms
-
The University of Texas Medical Branch, GalvestonCompletedLower Urinary Tract Symptoms | Lower Gastrointestinal Tract Symptoms
-
Far Eastern Memorial HospitalCompletedPsychiatric Aspects in Women With Lower Urinary Tract SymptomsTaiwan
-
Baylor Research InstituteForte MedicalCompletedLower Urinary Tract Symptoms | Lower Urinary Tract InfectionUnited States
-
Jagiellonian UniversityPiotr ChlostaCompletedTo Evaluate Lower Urinary Tract Symptoms (LUTS) in PolandPoland
-
Boston Scientific CorporationTerminatedBPH | BPH With Urinary Obstruction | BPH With Urinary Obstruction With Other Lower Urinary Tract SymptomsUnited States, Australia
-
Benaroya Research InstituteVirginia Mason Hospital/Medical CenterUnknownPain | BPH With Urinary Obstruction | BPH With Urinary Obstruction With Other Lower Urinary Tract SymptomsUnited States
-
San Carlo di Nancy HospitalLampugnani Farmaceutici S.p.A. (Nerviano, Milan, Italy)CompletedBPH With Urinary Obstruction With Other Lower Urinary Tract SymptomsItaly
Clinical Trials on UroLift as artifical device for prostatic urethral lift.
-
Queen Mary Hospital, Hong KongNot yet recruitingBPH With Urinary Obstruction